Safety and Efficacy of Bimekizumab in Patients With Active Psoriatic Arthritis: Three‐Year Results From a Phase IIb Randomized Controlled Trial and Its Open‐Label Extension Study

OBJECTIVE: To assess the long‐term safety, tolerability, and efficacy of bimekizumab in active psoriatic arthritis (PsA). METHODS: Adult patients with active PsA who completed the double‐ and dose‐blind periods of the BE ACTIVE randomized controlled trial were eligible to enroll in the open‐label ex...

Descripción completa

Detalles Bibliográficos
Autores principales: Coates, Laura C., McInnes, Iain B., Merola, Joseph F., Warren, Richard B., Kavanaugh, Arthur, Gottlieb, Alice B., Gossec, Laure, Assudani, Deepak, Bajracharya, Rajan, Coarse, Jason, Ink, Barbara, Ritchlin, Christopher T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Periodicals, Inc. 2022
Materias:
Psoriatic Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10100448/
https://www.ncbi.nlm.nih.gov/pubmed/35829656
http://dx.doi.org/10.1002/art.42280

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10100448/
https://www.ncbi.nlm.nih.gov/pubmed/35829656
http://dx.doi.org/10.1002/art.42280

Ejemplares similares